Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer - Article Botanicals; Herbalism; Medicinal Herbs
Clinical Trial: Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer
This study is no longer recruiting patients.
RATIONALE: Increasing knowledge about the complementary or alternative medicine practices used by women who are at increased risk for breast cancer may provide useful information for planning breast-cancer-prevention strategies. PURPOSE: Clinical trial to determine how many women who are at increased risk for breast cancer use complementary or alternative medicine.
|prevention of breast cancer |
MedlinePlus consumer health information
Study Type: Observational
Study Design: Natural History
Study start: June 2000
OBJECTIVES: I. Determine the prevalence of complementary or alternative medicine (CAM) practices among adult women enrolled in the Risk Assessment Clinic at the National Naval Medical Center Breast Care Center and found to be at increased risk for developing breast cancer. II. Correlate the use of CAM with individual risk for breast cancer. III. Define the types of CAM practices used by this study population. IV. Identify reasons why this study population is using CAM.
PROTOCOL OUTLINE: Patients are stratified according to prevalence of complementary and alternative medicine practices (enteral/parenteral vs psycho/neurologic). Patients complete a Personal Risk Assessment form, pre-test/post-test knowledge questionnaires, and a survey questionnaire.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 2 years.
Ages Eligible for Study: 18 Years and above
PROTOCOL ENTRY CRITERIA:
- Enrolled in the Risk Assessment Clinic (RAC) of the National Naval Medical Center and found to be at increased risk for breast cancer based on at least one of the following: Estimated risk of at least 1.7% for developing breast cancer over the next 5 years, as determined by the Breast Cancer Risk Assessment Tool (BCRAT); Prior history of lobular carcinoma in situ or ductal carcinoma in situ; Family history of breast or ovarian cancer consistent with autosomal dominant pattern of inheritance or empirically elevated risk of breast cancer based on a single first or second degree relative with breast or ovarian cancer
- Must have attended the RAC education session within past 3-6 months
- Hormone receptor status: Not specified
- Not specified
- Age: 18 and over
- Sex: Female
- Menopausal status: Not specified
- Performance status: Not specified
- Life expectancy: Not specified
- Hematopoietic: Not specified
- Hepatic: Not specified
- Renal: Not specified
- Other: No other prior cancer, except ductal carcinoma in situ or basal cell carcinoma; Able to read and understand English
Medicine Branch, Bethesda, Maryland, 20892, United States
National Naval Medical Center, Bethesda, Maryland, 20889-5000, United States
Paula Glauber, Study Chair, National Cancer Institute (NCI)
Record last reviewed: February 2004
Last Updated: October 13, 2004
Record first received: July 11, 2001
ClinicalTrials.gov Identifier: NCT00020098
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005